The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $6.01

Today's change+0.05 +0.84%
Updated December 9 4:00 PM -5GMT. Delayed by at least 15 minutes.
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $6.01

Today's change+0.05 +0.84%
Updated December 9 4:00 PM -5GMT. Delayed by at least 15 minutes.

Keryx Biopharmaceuticals Inc up (U.S.)$0.05

Keryx Biopharmaceuticals Inc closed up Friday by (U.S.)$0.05 or 0.84% to (U.S.)$6.01. Over the last five days, shares have gained 6.00% and 19.01% year to date. Shares have outperformed the S&P 500 by 23.21% during the last year.

Key company metrics

  • Open(U.S.) $6.00
  • Previous close(U.S.) $5.96
  • High(U.S.) $6.20
  • Low(U.S.) $5.87
  • Bid / Ask(U.S.) $4.00 / (U.S.) $6.20
  • YTD % change+19.01%
  • Volume1,192,749
  • Average volume (10-day)1,454,891
  • Average volume (1-month)1,694,414
  • Average volume (3-month)1,572,225
  • 52-week range(U.S.) $2.80 to (U.S.) $7.80
  • Beta5.06
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.56
Updated December 9 4:00 PM -5GMT. Delayed by at least 15 minutes.
S&P TSX0.11%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue6976
Total other revenue--------
Total revenue6976
Gross profit-13454
Total cost of revenue19622
Total operating expense48333031
Selling / general / administrative21202122
Research & development9788
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-42-24-23-25
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-42-45-41-38
Income after tax-42-45-41-38
Income tax, total0000
Net income-42-45-41-38
Total adjustments to net income--------
Net income before extra. items-42-45-41-38
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-42-45-41-38
Inc. avail. to common incl. extra. items-42-45-41-38
Diluted net income-42-45-41-38
Dilution adjustment00--0
Diluted weighted average shares106106106105
Diluted EPS excluding extraordinary itemsvalue per share-0.39-0.42-0.39-0.36
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.39-0.42-0.39-0.36